SynthesisBMC medical genomics2026
Association between the IGFBP-3 rs2854744 polymorphism and cancer risk: a meta-analysis.
Synthesis in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, the association of IGFBP-3 polymorphism and cancer risk has attracted many attentions. Previous studies have shown that IGFBP-3 rs2854744 was associated with cancer, but the results were conflicting. METHOD AND
resultsWe performed a meta-analysis including 33 studies with 24,688 cases and 28,972 controls to seek the association among them. A significant increase of cancer risk was found between the IGFBP-3 rs2854744 Polymorphism and cancer risk in Recessive Model (CC vs. AC/AA: OR = 1.097, 95%CI: 1.020, 1.180, P < 0.05). While in subgroup analysis, A same increase of breast cancer risk also have been shown in our study in Recessive Model (CC vs. AC/AA: OR = 1.126, 95%CI: 1.007, 1.260, P < 0.05).
conclusionsThe results of our meta-analysis concluded that the IGFBP-3 rs2854744 polymorphism was closely related with the increase of cancer risk while further large size case–control studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.